Shiying Li, Iulian Dragan, Van Du T Tran, Chun Ho Fung, Dmitry Kuznetsov, Michael K Hansen, Joline W J Beulens, Leen M 't Hart, Roderick C Slieker, Louise A Donnelly, Mathias J Gerl, Christian Klose, Florence Mehl, Kai Simons, Petra J M Elders, Ewan R Pearson, Guy A Rutter, Mark Ibberson
INTRODUCTION: Type 2 diabetes (T2D) onset, progression and outcomes differ substantially between individuals. Multi-omics analyses may allow a deeper understanding of these differences and ultimately facilitate personalised treatments. Here, in an unsupervised "bottom-up" approach, we attempt to group T2D patients based solely on -omics data generated from plasma. METHODS: Circulating plasma lipidomic and proteomic data from two independent clinical cohorts, Hoorn Diabetes Care System (DCS) and Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS), were analysed using Similarity Network Fusion...
2024: Frontiers in Endocrinology